Rising Treatments for Various Sclerosis.


85 views
Uploaded on:
Category: Art / Culture
Description
Rising Treatments for Various Sclerosis. Horea Rus MD PhD. affirmed. In stage II. Documented. In stage III. Existing Treatments and Rising Treatments for MS. 2005. 2006. 2007. 2010. 2011. 2012. 2013. Orals. Injectables. BG 12 Oral Fumarate. Oral Cladribine. Rebif. Teriflunomide.
Transcripts
Slide 1

Developing Therapies for Multiple Sclerosis Horea Rus MD PhD

Slide 2

sanction In stage II Filed In stage III Existing Therapies and Emerging Therapies for MS 2005 2006 2007 2010 2011 2012 2013 Orals Injectables BG 12 Oral Fumarate Oral Cladribine Rebif Teriflunomide Betaseron FTY 720 Laquinimod Copaxone SB683699 Fampridine ambulation sign? Avonex IV Novantrone IV Campath Tysabri Rituximab II - RRMS; III - PPMS Generic Mitoxantrone (oncology) (MS) Daclizumab MLN1202 MBP 8298

Slide 3

New Oral Therapies

Slide 4

Fingolimod (FTY720) A sphingosine - 1-phosphate inhibitor that reversibly sequester lymphocytes to lymph hubs

Slide 5

Fingolimod (FTY720) Phase II ponders: 281 patients got FTY 720 1.25 or 5 mg or placebo once day by day Primary end point : number of gadolinium improving sores Reduced the quantity of gadolinium upgrading injuries recognized on the cerebrum MRI and clinical sickness action Both measures diminished in patients who changed from placebo to fingoloimod

Slide 6

Proportions of Patients Who Were Free of Gadolinium-Enhanced Lesions on T1-Weighted MRI at 0 to 6 Months (Panel An) and the Estimated Time to a First Confirmed Relapse (Panel B) Kappos L et al. N Engl J Med 2006;355:1124-1140

Slide 7

Fingolimod Side impacts: Clinically asymptomatic rises of liver proteins Initial lessening of the heart rate Modest diminishing of constrained expiratory volume No genuine contaminations reported

Slide 8

Fingolimod (FTY720) Phase III Studies have started and patients can be alluded

Slide 9

FREEDOMS II: Inclusion Criteria Oral FTY720 0.5 & 1.25 mg once every day versus placebo Male and Females18 through 55 years old with a determination of various sclerosis by 2005 McDonald criteria EDSS score 0−5.5 comprehensive One reported backslide in the most recent year or two archived backslides in the most recent 2 years

Slide 10

TRANSFORMS: Inclusion Criteria Oral FTY720 0.5 & 1.25 mg once every day versus i.m. interferon β-1a (Avonexâ®) once week after week Treatment naã¯ve patients or patients effectively treated with MS medications can be screened. 18 - 55 years old with a finding of MS by 2005 McDonald criteria A backsliding transmitting course with no less than 1 recorded backslide amid the earlier year or 2 archived backslides amid the past 2 years Expanded Disability Status Scale (EDSS) score of 0-5.5 comprehensive

Slide 11

Cladribine Purine nucleoside with lymphocyte draining properties It upsets cell digestion system, prompts DNA harm and consequent cell passing. Was appeared to smother Gd-upgrading injuries in patients which got iv Cladribine for 12 months Reduced the recurrence of backslides

Slide 12

Cladribine Phase III study with oral Cladribine is progressing. 1290 patients enrolled; 10 mg Cladribine versus placebo for 5 days a month, 2-4 cycles a year. End focuses: Relapse rate, EDSS, MRI action Side impacts: Lymphopenia , however danger of artful diseases is low, constrained to segmental Herpes Zoster, one instance of fulminant hepatitis B Long term wellbeing of tablets utilize not settled

Slide 13

Laquinimod Oral immunomodulator Phase II - 306 patients randomized to either Laquinimod 0.3 or 0.6 mg/day or placebo; Significant lessening in total number of upgrading sores on cerebrum MRI for 36 weeks with 0.6 mg/day; Positive patterns on yearly backslide rates, backslide free subjects and time to first backslide; Phase III trials to start soon.

Slide 14

Fumaric corrosive derivate BG00012 Medication is utilized as a part of treatment of psoriasis Cytoprotective and calming impacts Phase II study : 235 patients were randomized to 120, 360 or 720 mg/day Reduced the quantity of new gadolinium –enhancing sores by 69% versus placebo Relapse rate in all treatment gatherings diminished as contrasted and placebo

Slide 15

Fumaric corrosive derivate BG00012 When patients on placebo were changed to BG00012 720 mg/day for the expansion stage the backslide rate was decreased by 52% Side impacts: Favorable wellbeing profile Reported: flushing,increased liver catalysts, no diseases Phase III in advancement

Slide 16

TERIFLUNOMIDE Analog of Leflunomide utilized as a part of the treatment of Rheumatoid Arthritis Inhibits a mitochondrial compound and multiplication of T and B Cells Phase II study: Two unique regimens: 7 and 14 mg/day versus Placebo for 36 weeks in 179 patients. Patients on Teriflunomide when contrasted and placebo had : Significantly decreased number of dynamic and new sores On the mind MRI A lower annualized backslide rate

Slide 17

TERIFLUNOMIDE Side impacts: Generally very much endured Most normal symptoms: upper respiratory tract diseases and cerebral pain In RA patients-dangerous liver putrefaction and pancytopenia have been portrayed.

Slide 18

Cumulative Number of Gd-Positive Lesions Annualized Relapse Rate Fingolimod (1.25 mg) - 43%, P < .001 - 55%, P = .009 Teriflunomide (7 mg) - 61%, P < .03 - 32%, NS Laquinimod (0.3 mg) - 44%, P = .05 No distinction BG00012 (720 mg) - 69%, P < .001 - 32%, NS Cladribine (2.1 mg) - 90%, P = .001 - 51%, NS Phase II Studies of New Oral Multiple Sclerosis Therapies

Slide 19

Conclusions – Oral treatments Potential advantages of oral medicines for changing the course of RRMS are critical. They will grow the alternatives accessible while enhancing the simplicity of organization Will diminish the expense of treatment (?). Power encourage new blends of operators Could prompt build adherence.

Slide 20

MONOCLONAL ANTIBODIES

Slide 21

Monoclonal immune response creation. From: The Neurologist 2006;12, 171

Slide 22

Chimeric and acculturated monoclonal immune response From: The Neurologist 2006;12, 171

Slide 23

Alemtuzumab Phase II study: - 334 patients, - 3 year information were accounted for at ECTRIMS 2007 73% diminishment in the danger for backslide following 3 years subsequent when contrasted with patients treated with interferon beta 1a 70% decrease in the danger for movement of clinically noteworthy handicap when contrasted with patients treated with Interferon beta 1a

Slide 24

Alemtuzumab in various sclerosis Humanized monoclonal counter acting agent against CD 52 From: The Neurologist 2006;12, 171

Slide 25

Alemtuzumab Side impacts: Six patients created ITP Infusion related symptoms Severe Infections were occasional Thyroid related occasions were less then expected Two stage III studies to begin: CARE-MS I - Alemtuzumab as a first line treatment CARE-MS II – Alemtuzumab in patients which kept on encountering backslides

Slide 26

RITUXIMAB IN MS Chimeric Monoclonal immunizer hostile to CD20 Stem Pro-B Pre-B Immature Transitional Activated Memory Plasma Cell CD20 T. Ito, H. Rus 2007

Slide 27

T. Ito, H. Rus 2007

Slide 28

RITUXIMAB IN MS Phase II Study: 104 patients 1000 mg iv x 2 91% relative diminishment in number of total number of Gd-improving injuries 58% Reduction in clinical backslides Decision on beginning stage III trial is pending

Slide 29

DACLIZUMAB IN MS Phase II CHOICE study: At 24 weeks, 75 patients in the 2 mg/kg gathering experienced 72% less new or augmented Gd+ by and large contrasted with the 77 patients who got a placebo (p=0.004). The 78 patients in the 1 mg/kg gathering encountered a 25% diminishment in new or developed injuries: did not accomplish measurable hugeness. Both daclizumab regimens uncovered a pattern in decreasing the annualized backslide rate contrasted with placebo (35%); did not reach factual noteworthiness.

Slide 30

MBP8298 in optional dynamic MS Synthetic peptide aa 82-98 of myelin fundamental protein Immunodominant focus for both B-and T-cells in MS patients with HLA haplotype DR2. Organization of the peptide results in long haul concealment of against MBP autoantibodies; Phase II study: 32 patients, took after for 24 months 500mg of MBP8298 at regular intervals. the HLADR2 positive responder gathering demonstrated a middle time to movement of 78 months as contrasted and year and a half for placebo Phase III study - selecting patients

Slide 31

endorsed In stage II Filed In stage III Existing Therapies and Emerging Therapies for MS 2005 2006 2007 2010 2011 2012 2013 Orals Injectables BG 12 Oral Fumarate Oral Cladribine Rebif Teriflunomide Betaseron FTY 720 Laquinimod Copaxone SB683699 Fampridine ambulation sign? Avonex IV Novantrone IV Campath Tysabri Rituximab II - RRMS; III - PPMS Generic Mitoxantrone (oncology) (MS) Daclizumab MLN1202 MBP 8298 .:tslides

Recommended
View more...